Christopher A Cottrell, Xiaozhen Hu, Jeong Hyun Lee, Patrick Skog, Sai Luo, Claudia T Flynn, Katherine R McKenney, Jonathan Hurtado, Oleksandr Kalyuzhniy, Alessia Liguori, Jordan R Willis, Elise Landais, Sebastian Raemisch, Xuejun Chen, Sabyasachi Baboo, Sunny Himansu, Jolene K Diedrich, Hongying Duan, Cheng Cheng, Torben Schiffner, Daniel L V Bader, Daniel W Kulp, Ryan Tingle, Erik Georgeson, Saman Eskandarzadeh, Nushin Alavi, Danny Lu, Troy Sincomb, Michael Kubitz, Tina-Marie Mullen, John R Yates, James C Paulson, John R Mascola, Frederick W Alt, Bryan Briney, Devin Sok, William R Schief
A protective human immunodeficiency virus (HIV) vaccine will likely need to induce broadly neutralizing antibodies (bnAbs). Vaccination with the germline-targeting immunogen eOD-GT8 60mer adjuvanted with AS01B was found to induce VRC01-class bnAb precursors in 97% of vaccine recipients in the IAVI G001 phase 1 clinical trial; however, heterologous boost immunizations with antigens more similar to the native glycoprotein will be required to induce bnAbs. Therefore, we designed core-g28v2 60mer, a nanoparticle immunogen to be used as a first boost following eOD-GT8 60mer priming...
May 22, 2024: Science Translational Medicine